» Articles » PMID: 29029117

The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardio-Thoracic Surgery (EACTS): Second Report

Abstract

Objectives: The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) was founded in Berlin, Germany. EUROMACS is supported fully by the European Association for Cardio-Thoracic Surgery (EACTS) and, since 2014, has functioned as a committee of the EACTS. The purpose of having the EUROMACS as a part of the EACTS is to accumulate clinical data related to long-term mechanical circulatory support for scientific purposes and to publish annual reports.

Methods: Participating hospitals contributed surgical and cardiological pre-, peri- and long-term postoperative data of mechanical circulatory support implants to the registry. Data for all implants performed from 1 January 2011 to 31 December 2016 were analysed. Several auditing methods were used to monitor the quality of the data. Data could be provided for in-depth studies, and custom data could be provided at the request of clinicians and scientists. This report includes updates of patient characteristics, implant frequency, mortality rates and adverse events.

Results: Fifty-two hospitals participated in the registry. This report is based on 2947 registered implants in 2681 patients. Survival of adult patients (>17 years of age) with continuous-flow left ventricular assist devices with a mean follow-up of 391 days was 69% (95% confidence interval 66-71%) 1 year after implantation. On average, patients were observed for 12 months (median 7 months, range 0-70 months). When we investigated for adverse events, we found an overall event rate per 100 patient-months of 3.56 for device malfunction, 6.45 for major bleeding, 6.18 for major infection and 3.03 for neurological events within the first 3 months after implantation.

Conclusions: Compared to the first EUROMACS report, the number of participating hospitals increased from 21 to 52 (+148%), whereas the number of registered implants more than tripled from 825 to 2947 (+257%). The increase in the number of participating hospitals led us to increase the quality control measures through data input control, on-site audits and statistical analyses.

Citing Articles

A minimum dataset for destination therapy with left ventricular assist device: the evidence that matters to decision makers.

Punal-Rioboo J, Faraldo Valles M, Nogueira Uzal N, Patrick H, Varela-Lema L Int J Technol Assess Health Care. 2025; 41(1):e8.

PMID: 39819482 PMC: 11811952. DOI: 10.1017/S0266462325000054.


Comparing surgical techniques and results of secondary ischemic mitral regurgitation: a state-of-the-art literature review.

Nappi F Ann Transl Med. 2024; 12(5):91.

PMID: 39507449 PMC: 11534758. DOI: 10.21037/atm-24-39.


Association between caseload volume and outcomes in left ventricular assist device implantations - a EUROMACS analysis.

Mihalj M, Reineke D, Just I, Mulzer J, Cholevas N, Hoermandinger C Eur J Heart Fail. 2024; 26(11):2400-2409.

PMID: 39206731 PMC: 11659493. DOI: 10.1002/ejhf.3418.


Surgical Management of Ischemic Cardiomyopathy Patients with Severe Left Ventricular Dysfunction: Is It Time to Reconsider Revascularization Surgery?.

Masroor M, Wang Y, Zhang C, Dong N J Cardiovasc Dev Dis. 2024; 11(7).

PMID: 39057607 PMC: 11276879. DOI: 10.3390/jcdd11070184.


Apixaban in bridge to transplant and destination LVAD - rationale and study design: the ApixiVAD trial.

Schnegg B, Deveza R, Hayward C ESC Heart Fail. 2024; 11(4):2387-2394.

PMID: 38650125 PMC: 11287292. DOI: 10.1002/ehf2.14782.